// App-Quantinova.ai

9051 : Dendritic-cell vaccine (DCVAC) with first line chemotherapy in patients with stage IV NSCLC primary analysis of phase 2, open-label, randomized, multicenter trial.

Researchers

Presenter

  • Libor Havel

Principal Investigators

  • Milada Zemanova

  • Milos Pesek

  • Vitezslav Kolek

  • Radek Spisek

  • Jirina Bartunkova

  • Ladislav Pecen

  • Inna Krasnopolskaya

  • Marketa Cernovska

Medical Centers

  • Thomayer's Hospital, 1st Faculty of Medicine of Charles University in Prague, Prague, Czech Republic

  • First Faculty of Medicine, Charles University, Prague, Czech Republic

  • Department of Pneumooncology, University Hospital in Pilsen, Plzen, Czech Republic

  • SOTIO a.s., Prague, Czech Republic

  • University Hospital Motol, Prague, Czech Republic

  • Thomayer hospital, Prague, Czech Republic

Locations

  • Czech Republic

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Dendritic cell vaccine

  • Hydroxychloroquine

  • Carboplatin

  • Paclitaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved